Cardiff Oncology (Cardiff Oncology) Margin of Safety % (DCF FCF Based) : N/A (As of Apr. 27, 2024)

View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Cardiff Oncology's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Cardiff Oncology's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Cardiff Oncology's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiff Oncology's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Margin of Safety % (DCF FCF Based) falls into.

Cardiff Oncology Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiff Oncology (Cardiff Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (NAS:CRDF) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

XE7C:Germany

Address

11055 Flintkote Avenue, San Diego, CA, USA, 92121

Website

https://www.cardiffoncology.com

Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Executives

Gary W Pace	director	C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Fairooz Kabbinavar	officer: Chief Medical Officer	C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark Erlander	officer: Chief Scientific Officer	C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121
Lale White	director	310 GODDARD, SUITE 150, IRVINE CA 92618
James O Armitage	director	C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
James E. Levine	officer: Chief Financial Officer	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Renee P Tannenbaum	director	9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Tod Smeal	officer: Chief Scientific Officer	11055 FLINTKOTE AVENUE, SA DIEGO CA 92121
Katherine L Ruffner	officer: Chief Medical Officer	11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
Mani Mohindru	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Rodney S Markin	director	C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135
Gary S Jacob	director
Vicki Kelemen	officer: Exec. VP and COO	11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116